Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)

Evaristo Maiello, Gabriele Di Maggio, Stefano Cordio, Saverio Cinieri, Francesco Giuliani, Salvatore Pisconti, Antonio Rinaldi, Antonio Febbraro, Tiziana Pia Latiano, Michele Aieta, Antonio Rossi, Daniele Rizzi, Massimo Di Maio, Giuseppe Colucci, Roberto Bordonaro

Research output: Contribution to journalArticlepeer-review

Abstract

Bevacizumab plus either FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) or XELOX-2 (capecitabine plus oxaliplatin) is among standard first-line treatment options in patients with metastatic colorectal cancer. This phase II randomized non-comparative trial evaluated the first-line combination of bevacizumab with either FOLFOX-4 or biweekly XELOX-2 in patients with metastatic colorectal cancer. Comparable response and a better tolerability for bevacizumab plus XELOX-2 was reported.

Original languageEnglish
Pages (from-to)109-115
Number of pages7
JournalClinical Colorectal Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Capecitabine
  • Elderly
  • Fluoropyrimidine
  • Frail
  • Non-comparative

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)'. Together they form a unique fingerprint.

Cite this